.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Recognizing and Managing Cancer-Associated Lambert-Eaton Myasthenic Syndrome

Panelists discuss how earlier recognition, targeted testing, guideline-informed screening, and coordinated oncology–neurology care can improve diagnosis and management of CA-LEMS, particularly when linked to small cell lung cancer.

EP. 1: Clinical Presentation and Early Identification of Cancer-Associated LEMS

December 10th 2025

Panelists discuss how early segment-level recognition of CA-LEMS hinges on spotting hallmark clinical cues (proximal lower-extremity weakness, autonomic dysfunction, and reflexes that transiently improve after exercise) and not dismissing symptoms as deconditioning or cancer-treatment effects, given frequent links to SCLC and other malignancies.

EP. 2: Understanding CA-LEMS Pathophysiology

December 10th 2025

Panelists discuss how CA-LEMS biology reflects an off-target antitumor immune response (often with SCLC) that generates antibodies against presynaptic VGCCs, reducing acetylcholine release and causing proximal weakness with brief strength improvement after repeated activation.

Recognizing and Managing Cancer-Associated Lambert-Eaton Myasthenic Syndrome

EP. 1: Clinical Presentation and Early Identification of Cancer-Associated LEMS

EP. 2: Understanding CA-LEMS Pathophysiology

EP. 3: Treatment Strategies for CA-LEMS

EP. 4: Monitoring and Optimizing Treatment Response in LEMS Management

EP. 5: NCCN Guidelines and Management of CA-LEMS in the Practice

EP. 6: Multidisciplinary Collaboration to Improve Early Recognition and Care For CA-LEMS